文献速递淋巴瘤

多柔比星与香港弥漫大B细胞淋巴瘤幸存者后续心血管疾病风险

Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong.
PubMed 文献 · Blood Adv · 2020-01-01

调整混杂因素后,多柔比星累积剂量>500 mg组CVD的病因特异性风险比为2.65(95%CI 1.23-5.74;基线高血压及使用阿司匹林/ACEI/β受体阻滞剂可能与更高CVD风险相关。

要点

  • 多柔比星累积剂量>500 mg与DLBCL幸存者后续CVD风险独立相关(HR 2.65)。
  • 患者15年CVD累积发生率为12.8%,显著高于匹配对照的5.2%。
  • 基线高血压及心血管药物使用可能进一步增加CVD风险。

核心结论

  • 多柔比星绝对剂量>500 mg与DLBCL幸存者后续CVD的病因特异性累积发生率升高相关。
  • 基线高血压或使用心血管风险因素药物可能进一步增加后续CVD风险。

研究设计与样本

  • 采用灵活参数竞争风险分析评估CVD的病因特异性累积发生率(csCI),并调整人口学、合并症、治疗暴露、心血管风险因素及生活方式因素。

主要发现

  • 患者5年、10年、15年csCI分别为8.2%、11.3%、12.8%,对照分别为3.1%、4.4%、5.2%。

临床怎么用

  • 对接受多柔比星累积剂量>500 mg的DLBCL幸存者,应加强心血管风险监测与随访。
  • 评估基线高血压及心血管药物使用情况,据此制定风险适配的个体化随访策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence regarding the dose-related impact of doxorubicin on subsequent cardiovascular diseases (CVDs) in Asian patients with diffuse large B-cell lymphoma (DLBCL) without preexisting CVDs is lacking. From a territory-wide electronic database in Hong Kong, we identified adults who were diagnosed with DLBCL and treated with chemotherapy between 2000 and 2018. We evaluated the patients for incident CVDs (including ischemic heart disease, heart failure, and cardiomyopathy). We evaluated the cause-specific cumulative incidence (csCI) of CVD with levels of doxorubicin exposure by using flexible parametric competing risk analysis and adjusting for demographics, comorbidities, therapeutic exposure, cardiovascular risk factors, and lifestyle factors. Controls were age- and sex-matched to DLBCL patients. We analyzed 2600 patients and 13 000 controls. The adjusted cause-specific hazard ratio (HR) for CVD in patients treated with >500 mg doxorubicin compared with non-doxorubicin regimens was 2.65 (95% confidence interval [CI], 1.23-5.74; P = .013). The 5-, 10-, and 15-year csCIs were 8.2%, 11.3%, and 12.8% in patients vs 3.1%, 4.4%, and 5.2% in controls, respectively. Hypertension (HR, 6.20; 95% CI, 0.79-48.44; P = .082) and use of aspirin/angiotensin-converting enzyme inhibitor/beta-blocker at baseline (HR, 2.13-4.63; P < .001 to .002) might confer a higher risk of subsequent CVDs. In this Hong Kong population-based study, doxorubicin exposure (absolute dose >500 mg), together with hypertension or baseline use of medication for cardiovascular risk factors, was found to be associated with an increase in csCIs of CVDs. Tailoring therapeutic strategies to underlying CVD risk factors and risk-adapted monitoring and follow-up of susceptible DLBCL patients are advisable.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lee SF, Luque-Fernandez MA, Chen YH, et al. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong. Blood Adv. 2020. PMID: 33085755. doi:10.1182/bloodadvances.2020002737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。